molecular
diagnost
test
base
detect
identif
nucleic
acid
human
biolog
sampl
increasingli
employ
diagnosi
infecti
diseas
may
futur
benefit
cf
microbiolog
servic
grow
understand
complex
polymicrobi
natur
cf
airway
infect
highlight
current
like
futur
shortcom
standard
diagnost
practic
failur
detect
fastidi
slow
grow
microb
misidentif
newli
emerg
pathogen
could
potenti
address
use
cultureindepend
molecular
technolog
high
target
specif
review
consid
exist
molecular
diagnost
test
context
key
requir
envisag
cf
microbiolog
focuss
assay
issu
assay
speed
throughput
detect
multipl
pathogen
data
interpret
antimicrobi
suscept
test
discuss
recent
year
nucleic
acid
base
technolog
increasingli
exploit
human
health
analysi
human
gene
detect
analysi
pathogen
microorgan
assay
target
human
gene
express
use
screen
identifi
peopl
increas
risk
diseas
diagnosi
hereditari
condit
detect
diseas
associ
biomark
predict
monitor
respons
treatment
microbi
nucleic
acid
target
diagnosi
infecti
diseas
identifi
epidem
strain
pathogen
trait
predict
monitor
respons
treatment
molecular
test
promot
within
clinic
diagnost
due
potenti
rapid
deliveri
result
high
sampl
throughput
accuraci
sensit
reproduc
focu
review
potenti
use
molecular
test
routin
clinic
practic
detect
identifi
respiratori
pathogen
associ
cystic
fibrosi
cf
lung
infect
major
caus
morbid
mortal
cf
patient
improv
antibiot
therapi
contribut
toward
increas
life
expect
improv
abil
determin
presenc
pathogen
would
allow
direct
treatment
may
improv
outcom
patient
context
routin
patient
care
treatment
infect
exacerb
detect
identif
cf
pathogen
diagnost
microbiolog
prove
benefici
sever
way
monitor
peopl
cf
infanc
promot
earli
discoveri
newli
acquir
infect
therebi
increas
likelihood
erad
though
time
treatment
earli
erad
pseudomona
aeruginosa
recognis
contribut
better
patient
outcom
reduc
treatment
cost
furthermor
provid
direct
evid
respons
antibiot
treatment
goal
expect
complet
clear
infect
may
consequ
clinic
failur
erad
p
aeruginosa
infect
children
link
higher
risk
subsequ
exacerb
may
indic
emerg
chronic
infect
routin
outpati
clinic
also
commonli
segreg
accord
infect
type
limit
crossinfect
patient
cohort
colonis
burkholderia
cepacia
complex
bcc
meticillinresist
staphylococcu
aureu
mrsa
p
aeruginosa
infect
type
also
implic
organis
inpati
care
admiss
separ
ward
provis
individu
room
prefer
en
suit
facil
regular
microbiolog
surveil
detect
cf
airway
pathogen
recommend
best
practic
cf
patient
care
depend
diseas
sever
cystic
fibrosi
trust
european
cystic
fibrosi
societi
ecf
advoc
routin
outpati
checkup
time
per
year
clinic
stabl
patient
addit
respiratori
sampl
analys
follow
diagnosi
pulmonari
exacerb
order
guid
choic
antibiot
therapi
exacerb
usual
treat
intraven
antibiot
hospit
set
homecar
support
least
day
treatment
recommend
cystic
fibrosi
trust
weekli
microbiolog
cultur
recommend
ecf
durat
treatment
microb
clinic
relev
cf
lung
diseas
tradit
clinic
impact
cf
lung
infect
attribut
role
play
small
number
pathogen
name
p
aeruginosa
haemophilu
influenza
aureu
b
cepacia
whilst
bacteri
speci
associ
increas
morbid
mortal
earli
identif
cf
pathogen
may
arisen
least
part
rel
eas
detect
cultur
practic
employ
time
convers
practic
may
detect
fastidi
anaerob
slow
grow
pathogen
recent
year
complex
cf
lung
infect
increasingli
recognis
convent
cfrelat
bacteria
p
aeruginosa
h
influenza
aureu
b
cepacia
stenotrophomona
maltophilia
achromobact
xylosoxidan
found
absent
sputum
patient
pulmonari
exacerb
enhanc
cultur
molecular
techniqu
identifi
presenc
unexpectedli
divers
rang
previous
undetect
bacteria
fungi
virus
role
mani
newli
detect
speci
cf
lung
diseas
unclear
studi
ongo
determin
pathogen
clinic
relev
primari
infecti
agent
includ
bacteria
fungi
virus
current
consid
relev
cf
record
tabl
technolog
develop
field
molecular
microbiolog
provid
opportun
reassess
list
microb
tradit
associ
cf
lung
infect
recent
year
rang
dna
base
techniqu
exploit
ribosom
rna
gene
sequenc
detect
identif
bacteri
speci
taxa
methodolog
includ
termin
restrict
fragment
length
polymorph
trflp
phylogenet
hybridis
microarray
clone
librari
sequenc
next
gener
sequenc
initi
microbiota
studi
tend
qualit
describ
wide
divers
bacteria
detect
howev
recent
quantit
pyrosequenc
data
publish
largest
longitudin
studi
date
follow
patient
year
sampl
collect
whilst
largest
crosssect
studi
analys
singl
sampl
patient
third
studi
analys
sputum
sampl
patient
monitor
effect
antibiot
treatment
commun
composit
whilst
two
investig
analys
sampl
patient
sampl
patient
respect
bacteri
genera
detect
n
abund
least
one
cf
patient
studi
record
tabl
although
high
abund
speci
genu
necessarili
signifi
pathogen
identifi
potenti
clinic
impact
may
indic
increas
health
risk
speciesgenera
found
harm
major
genera
report
n
abund
belong
firmicut
proteobacteria
actinobacteria
bacteroidet
phyla
pseudomona
streptococcu
prevotella
rothia
genera
detect
n
least
one
patient
five
studi
investig
vari
greatli
design
scope
involv
heterogen
patient
group
data
requir
give
accur
pictur
typic
rel
abund
bacteria
found
cf
lung
furthermor
increas
evid
point
reduct
divers
lung
diseas
progress
therebi
link
microbi
commun
composit
clinic
statu
thu
may
accur
consid
differ
microbi
commun
profil
typic
specif
stage
patient
health
detect
bacteri
speci
respiratori
sampl
necessarili
mean
clinic
import
role
infect
determin
impact
pose
major
challeng
research
clinician
ultim
speci
deem
clinic
relev
shown
clinic
sign
symptom
wors
patient
present
compar
patient
absent
howev
number
key
factor
help
predict
potenti
clinic
impact
differ
genera
detect
includ
exampl
data
current
exist
demonstr
clinic
impact
anaerob
genera
found
cf
lung
howev
speci
detect
includ
known
oral
pathogen
possess
virul
gene
demonstr
virul
vitro
mous
lung
infect
model
abund
preval
cf
lung
contribut
core
microbiota
addit
cf
patient
found
antibodi
two
immunoreact
antigen
prevotella
intermedia
thu
applic
criteria
suggest
anaerob
speci
may
signific
cf
lung
diseas
warrant
investig
antimicrobi
therapi
gener
target
new
infect
noncolonis
patient
predomin
pathogen
chronic
colonis
patient
current
presenc
acquisit
addit
infect
chronic
colonis
patient
unlik
alter
treatment
chronic
infect
tend
treat
broad
spectrum
antibiot
target
predomin
pathogen
antibiot
thought
effect
major
convent
recognis
cf
pathogen
nevertheless
treatment
may
sometim
use
directli
exist
nonpredomin
pathogen
target
increas
maltophilia
associ
use
antipseudomon
antibiot
nontubercul
mycobacteria
may
also
warrant
specif
treatment
knowledg
gain
polymicrobi
natur
cf
infect
futur
treatment
practic
may
chang
consider
might
includ
prescrib
antibiot
effect
anaerob
target
bacteria
increas
pathogen
princip
pathogen
order
facilit
appropri
target
treatment
infect
speci
deem
pathogen
must
first
effect
strategi
detect
identif
current
practic
diagnosi
cf
infect
depend
microbi
cultur
patient
sputum
cough
swab
oropharyng
swab
bronchoalveolar
lavag
bal
sampl
cystic
fibrosi
trust
guidelin
recommend
use
sever
select
nonselect
agar
occasion
liquid
cultur
maximis
detect
pathogen
commonli
implic
cf
infect
suspect
pathogen
isol
subsequ
identif
inform
combin
visual
characterist
biochemistri
test
commerci
phenotypicbas
kit
instrument
pcr
amplificationsequenc
gene
specif
individu
pathogen
matrixassist
laser
desorpt
ionisationtim
flight
mass
spectrometri
malditof
ms
also
use
case
consult
specialist
refer
laboratori
may
requir
vitro
antibiot
suscept
predomin
pathogen
also
typic
determin
standard
diagnost
microbiolog
take
sever
day
definit
report
requir
highli
specialis
knowledg
experi
gain
mani
year
challeng
appli
techniqu
effect
highlight
two
recent
qualiti
assess
trial
observ
signific
shortcom
laboratori
across
europ
provid
microbiolog
servic
larg
cf
centr
trial
assess
laboratori
identif
microbi
speci
respiratori
specimen
either
singl
isol
mixtur
nine
formul
sent
laboratori
common
pathogen
p
aeruginosa
aureu
aureu
small
coloni
variant
correctli
identifi
whilst
uncommon
newli
emerg
pathogen
frequent
detect
misidentifi
exampl
xylosoxidan
pandoraea
pnomenusa
receiv
incompletewrong
identif
tabl
bacteri
genera
report
detect
abund
lung
least
one
cf
patient
bacteri
phylumgenu
zhao
et
al
n
fodor
et
al
n
filkin
et
al
n
delha
et
al
n
guss
et
al
n
addit
unexpect
deficit
uncov
trial
author
suggest
particip
laboratori
specif
select
size
research
activ
might
expect
smaller
laboratori
would
perform
less
well
identif
failur
may
due
difficulti
associ
commonli
use
phenotyp
identif
system
low
biochem
reactiv
bacteria
test
loss
characterist
phenotyp
chronic
colonis
absenc
commerci
databas
number
speci
recognis
potenti
pathogen
context
increas
routin
diagnost
cf
microbiolog
like
becom
even
complex
would
present
increas
challeng
respect
detect
cultur
subsequ
correct
identif
pathogen
detect
convent
cultur
complic
problem
slow
grow
fastidi
microb
overgrown
abund
faster
grow
organ
lack
routin
cultur
condit
appropri
growth
emerg
pathogen
issu
may
result
clinic
relev
microb
overlook
whilst
extens
cultur
method
use
multipl
combin
special
media
growth
condit
detect
major
cf
bacteria
identifi
molecular
method
cf
sputum
approach
practic
routin
clinic
laboratori
continu
relianc
culturebas
method
would
necessit
expans
exist
clinic
cultur
procedur
includ
labori
potenti
demand
practic
enabl
reproduc
detect
newli
emerg
pathogen
case
anaerob
bacteria
clinic
relev
demonstr
difficulti
associ
effect
anaerob
cultur
would
address
highlight
recent
studi
evalu
cultur
protocol
pathogen
identif
bal
sampl
cf
patient
author
report
anaerob
cultur
either
neg
overgrown
aerob
therefor
diagnost
ineffect
yet
culturebas
studi
abl
detect
isol
anaerob
major
sputum
sampl
addit
incid
abund
potenti
fungal
pathogen
cf
sputum
found
vari
geograph
region
like
due
lack
appropri
standardis
cultur
practic
similar
inconsist
north
american
cf
site
also
report
detect
tradit
cf
bacteri
pathogen
prior
standardis
clinic
laboratori
practic
furthermor
although
virus
recognis
contribut
patient
poor
health
link
pulmonari
exacerb
sputum
sampl
routin
screen
presenc
whilst
fastidi
growth
limit
cultur
practic
may
contribut
fail
detect
cf
pathogen
misidentif
incomplet
identif
also
common
investig
molecular
method
detect
identif
bacteria
cf
sputum
convent
phenotyp
method
incorrectli
identifi
known
pathogen
isol
children
cf
bacteria
adult
patient
recent
malditof
ms
appli
identif
bacteri
isol
match
protein
mass
spectra
commerci
librari
predetermin
refer
spectra
two
system
bruker
biotyp
ms
matrixassist
laser
desorpt
ionisationtim
flight
mass
spectrometri
system
evalu
biochem
molecular
refer
method
identif
nonfer
gramneg
bacilli
isol
cf
patient
sputa
instrument
perform
well
bruker
biotyp
vitek
ms
agre
refer
identif
combin
speciescomplexgenu
level
isol
respect
trial
also
demonstr
use
malditof
ms
definit
identif
bcc
isol
speci
level
bruker
instrument
addit
test
directli
cf
sputum
pathogen
identif
without
prior
cultur
less
suitabl
applic
mean
although
malditof
ms
improv
identif
bacteria
sensit
current
limit
effici
routin
sampl
cultur
pathogen
isol
nevertheless
malditof
ms
increasingli
employ
clinic
diagnost
laboratori
distinct
advantag
tradit
phenotyp
identif
method
recent
studi
found
isol
cf
patient
identifi
malditof
ms
within
h
sampl
incub
compar
convent
method
particular
p
aeruginosa
isol
identifi
day
aureu
isol
day
malditof
ms
contrast
p
aeruginosa
isol
aureu
isol
identifi
day
use
convent
method
author
conclud
adopt
technolog
would
reduc
time
result
report
clinic
care
team
ultim
lead
improv
patient
outcom
addit
switch
malditof
ms
observ
cheaper
routin
bacteri
identif
addit
report
presenc
clinic
import
bacteri
speci
convent
diagnost
microbiolog
also
provid
inform
antibiot
suscept
isol
inform
gener
use
guid
therapi
choic
howev
test
reproduc
poorli
predict
clinic
outcom
manag
pulmonari
exacerb
caus
p
aeruginosa
adult
paediatr
cf
patient
furthermor
recent
retrospect
review
pulmonari
exacerb
occur
centr
year
period
patient
chronic
infect
p
aeruginosa
pulmonari
exacerb
success
treat
regimen
contain
antibiot
deem
activ
cultur
bacteria
determin
vitro
suscept
test
lack
concord
vitro
test
clinic
outcom
may
result
standard
vitro
cultur
method
accur
reflect
highli
complex
microbi
commun
environment
condit
found
cf
lung
relev
issu
includ
inher
phenotyp
divers
instabl
within
chronic
infect
p
aeruginosa
popul
biofilm
growth
anaerobicmicroaerophil
condit
nichespecif
nutrit
metabol
potenti
interspeci
interact
furthermor
attempt
develop
clinic
relev
suscept
test
combin
biofilm
direct
test
shown
consist
improv
clinic
bacteriolog
outcom
mani
molecular
diagnost
method
requir
growth
isol
microorgan
instead
reli
detect
target
nucleic
acid
three
major
approach
microbi
identif
use
nucleic
acid
extract
clinic
sampl
first
use
sequenc
specif
hybridis
customdesign
primer
andor
probe
detect
dna
rna
individu
microbi
target
gener
pcr
amplif
rang
hybridisationbas
assay
vari
design
alreadi
use
routin
clinic
practic
infecti
diseas
diagnosi
two
approach
base
sequenc
pcrmass
spectrometri
recent
emerg
technolog
yet
adopt
routin
clinic
practic
except
two
sequenc
base
assay
genotyp
system
celera
diagnost
genotyp
open
gene
dna
sequenc
system
siemen
healthcar
diagnost
develop
hiv
drug
resist
test
regulatori
legisl
govern
whether
commerci
diagnost
test
market
vitro
diagnost
clinic
use
sale
within
europ
usa
entail
ce
mark
fda
approv
respect
whilst
regul
outsid
region
vari
nation
approv
requir
evalu
assay
sensit
specif
well
proof
manufactur
consist
stabil
test
reagent
guarante
reliabl
within
perform
paramet
claim
date
fda
approv
molecular
test
manufactur
clinic
detect
identif
bacteri
viral
fungal
infect
variou
human
biolog
sampl
base
hybridis
technolog
central
major
test
amplif
nucleic
acid
sequenc
uniqu
target
pathogen
amplifi
region
amplicon
detect
via
report
molecul
either
amplif
step
polymeras
chain
reaction
pcr
first
still
commonli
employ
method
amplif
dna
target
adapt
rna
target
viral
genom
ad
initi
revers
transcript
step
known
rtpcr
recent
altern
amplif
techniqu
develop
adopt
commerci
molecular
diagnost
due
lower
run
cost
reduc
reaction
time
realtim
pcr
combin
target
amplif
detect
singl
process
approxim
half
manufactur
fda
approv
test
detect
infecti
agent
employ
realtim
pcr
technolog
assay
altern
test
target
amplif
detect
separ
detect
method
involv
bind
targetspecif
probe
use
secondari
nest
targetspecif
pcr
order
futur
molecular
diagnost
assay
improv
upon
current
cf
microbiolog
practic
defin
requir
assay
would
effici
detect
accur
identif
multipl
cfassoci
pathogen
directli
patient
sampl
clinic
benefici
timescal
initi
minimum
specif
includ
pathogen
list
expert
bodi
clinic
relev
tabl
howev
assay
flexibl
would
requir
allow
futur
inclus
speci
deem
clinic
relev
addit
desir
featur
fulli
satisfi
current
methodolog
may
includ
capabl
quantit
report
antibiot
suscept
measur
predict
vivo
respons
full
autom
within
contain
environ
would
also
highli
desir
would
improv
assay
robust
reduc
risk
oper
error
sampl
contamin
number
consider
applic
potenti
molecular
diagnost
format
ensur
deliveri
good
qualiti
data
truli
repres
vivo
microbiota
issu
discuss
comprehens
roger
bruce
review
address
clinic
applic
nextgener
sequenc
human
microbiom
includ
detect
cf
pathogen
particular
author
emphasis
care
consider
given
repeat
sampl
maximum
coverag
commun
divers
requir
b
exclus
extracellular
dna
dna
dead
cell
quantit
measur
c
develop
robust
dna
extract
protocol
equal
effici
speci
present
exclus
pcr
contamin
includ
exogen
dna
commerci
reagent
fda
approv
test
alreadi
exist
detect
pathogen
relev
cf
streptococcu
spp
aureu
mrsa
h
influenza
influenza
virus
b
respiratori
syncyti
virus
b
howev
major
import
cf
airway
pathogen
overlook
includ
p
aeruginosa
bcc
thu
none
current
avail
test
combin
test
adequ
comprehens
cf
microbiolog
routin
clinic
purpos
nevertheless
technolog
involv
exist
test
perhap
exist
test
could
adapt
valid
detect
cf
lung
pathogen
key
aspect
molecular
assay
design
signific
clinic
cf
microbiolog
multiplex
throughput
autom
data
interpret
recent
develop
molecular
approach
antimicrobi
suscept
test
describ
outlin
cf
respiratori
sampl
may
contain
one
pathogen
interest
detect
clinic
relev
pathogen
futur
molecular
cf
microbiolog
assay
would
detect
number
separ
target
one
solut
would
run
multipl
singl
target
test
consecut
parallel
delay
speed
report
limit
sampl
throughput
respect
multipl
reaction
would
also
increas
cost
requir
larger
sampl
volum
altern
multiplex
could
use
combin
multipl
distinct
test
singl
assay
allow
simultan
detect
identif
individu
target
present
mixtur
date
six
manufactur
sell
fda
approv
molecular
diagnost
test
infecti
diseas
multiplex
detect
target
half
test
use
realtim
pcrrtpcr
multiplex
target
three
manufactur
employ
highli
multiplex
pcr
rtpcr
amplif
target
differ
mode
detect
identif
detect
identif
pathogen
list
tabl
requir
comprehens
diagnost
cf
microbiolog
singl
highli
multiplex
assay
would
prefer
maximis
throughput
whilst
minimis
timetoresult
one
key
benefit
molecular
diagnost
suitabl
autom
clear
potenti
benefit
term
assay
speed
sampl
throughput
requir
minim
oper
input
practic
autom
tend
balanc
flexibl
instrumentrun
cost
throughput
test
ie
number
result
gener
within
defin
time
period
govern
three
parametersth
durat
singl
test
degre
target
multiplex
per
test
number
test
run
singl
reaction
number
sampl
test
parallel
either
batch
stagger
interv
prioriti
throughput
requir
laboratori
suppli
diagnost
cf
microbiolog
servic
would
drive
degre
autom
design
potenti
molecular
cf
microbiolog
diagnost
assay
exist
system
alreadi
fda
approv
diagnosi
specifi
infecti
diseas
provid
exampl
autom
strategi
multiplex
test
could
applic
cf
includ
fulli
autom
system
oper
independ
sampletoresult
semiautom
system
frequent
divid
workflow
test
sampl
prepar
includ
dna
extract
assay
setup
assay
data
analysisresult
report
step
autom
separ
perform
manual
typic
manual
intervent
requir
step
exampl
instrument
approv
fda
defin
purpos
provid
tabl
compar
fulli
autom
semiautom
assay
tend
increas
overal
test
run
time
make
larger
batch
size
andor
high
multiplex
import
maximis
throughput
moreov
semiautom
assay
may
requir
signific
input
skill
technic
staff
test
procedur
data
interpret
alreadi
state
current
fda
approv
molecular
diagnost
assay
suitabl
complet
cf
microbiolog
analysi
howev
sever
fullyor
semiautom
instrument
capabl
multiplex
test
fdaapprov
diagnosi
respiratori
pathogen
sputum
sampl
indic
suitabl
technolog
alreadi
exist
could
transfer
cf
microbiolog
appropri
assay
develop
order
illustr
potenti
technolog
sampl
throughput
rate
perform
paramet
exist
multiplex
respiratori
pathogen
assay
current
fda
approv
clinic
vitro
diagnost
use
record
tabl
fulli
autom
system
list
test
singl
sampl
independ
complet
close
system
rapid
timetoresult
capabl
requir
less
minut
handson
time
per
sampl
higher
throughput
achiev
fulli
autom
system
use
sever
standalon
instrument
employ
modular
setup
one
central
control
run
numer
assay
independ
individu
assay
unit
current
cf
microbiolog
servic
inform
clinician
cfassoci
pathogen
detect
sampl
extent
provid
semiquantit
inform
term
rel
abund
domin
pathogen
order
futur
molecular
cf
microbiolog
assay
valuabl
clinic
data
gather
must
similarli
interpret
compil
action
report
major
fda
approv
molecular
assay
output
qualit
target
presenc
absenc
report
without
indic
much
target
present
research
shown
molecular
assay
employ
target
specif
amplif
frequent
sensit
cultur
combin
remov
speci
bia
introduc
standard
growth
condit
would
expect
enabl
molecular
report
microb
ordinarili
overlook
current
practic
whilst
advantag
patient
health
enabl
earlier
detect
pathogen
high
clinic
impact
p
aeruginosa
valu
increas
sensit
might
contenti
result
detect
pathogen
present
constant
level
may
low
affect
patient
health
yet
minimum
threshold
level
associ
wors
patient
outcom
establish
major
pathogen
thu
data
output
futur
molecular
cf
microbiolog
assay
might
initi
difficult
interpret
clinic
signific
threshold
establish
assay
sensit
adjust
appropri
note
lack
definit
threshold
also
appli
current
culturedepend
method
clinic
signific
bacteria
detect
usual
judg
subject
clinic
microbiologist
avail
quantit
molecular
report
could
benefici
particularli
indic
respons
treatment
chronic
infect
howev
technolog
yet
wide
adopt
infecti
diseas
diagnosi
test
current
fda
approv
quantit
realtim
pcr
assay
hepat
b
c
virus
human
immunodefici
viru
manufactur
abbott
roch
siemen
interestingli
seegen
recent
launch
quantit
toce
tm
technolog
design
return
semiquantit
result
realtim
target
singl
multiplex
reaction
among
plan
assay
assay
aim
detect
differenti
quantifi
respiratori
viral
pathogen
associ
upper
respiratori
diseas
success
technolog
might
futur
provid
use
basi
semiquantit
molecular
cf
microbiolog
test
whilst
antibiot
suscept
test
typic
practic
guid
choic
therapi
recommend
cystic
fibrosi
trust
earli
intermitt
p
aeruginosa
isol
ecf
determin
suscept
resist
pathogen
unusu
antibiot
use
question
howev
cultureindepend
assay
replac
convent
diagnost
microbiolog
provid
equival
inform
repres
signific
challeng
antibiot
resist
common
cf
pathogen
includ
domin
pathogen
p
aeruginosa
resist
intrins
bacteria
develop
mean
spontan
mutat
horizont
gene
transfer
manifest
number
mechan
includ
reduc
outer
membran
permeabl
activ
efflux
cell
target
alter
prevent
bind
enzymat
inactiv
drug
molecul
presenc
absenc
resist
gene
relev
cf
could
determin
molecularli
target
specif
amplif
exampl
use
technolog
current
fda
approv
assay
includ
detect
vancomycin
resist
gene
vana
meca
confer
meticillin
resist
mrsa
convers
detect
gene
mutat
convey
resist
cf
pathogen
would
complic
exampl
current
fda
approv
assay
capabl
detect
drug
resist
acquir
gene
mutat
employ
sequenc
technolog
vitro
antibiot
suscept
test
cf
pathogen
continu
requir
detect
specif
resist
gene
would
insuffici
predict
vivo
respons
given
mani
mode
resist
exploit
addit
gene
sequenc
may
impract
due
number
gene
potenti
involv
addit
effect
altern
approach
could
base
semimolecular
method
describ
sever
format
antibiot
suscept
test
blood
cultur
bacillu
anthraci
bacteria
commonli
isol
clinic
laboratori
includ
aureu
h
influenza
p
aeruginosa
essenc
bacteri
isol
blood
cultur
grown
without
antibiot
quantit
realtim
pcr
detect
rrna
gene
target
use
measur
differ
growth
indic
antibiot
suscept
resist
methodolog
report
accur
scenario
test
gener
rapid
convent
test
method
consider
advanc
nextgener
sequenc
technolog
past
year
greatli
enhanc
quantiti
speed
data
output
along
appreci
reduct
cost
make
sequenc
increasingli
realist
option
molecular
diagnosi
emerg
technolog
exist
commerci
platform
comprehens
review
perform
compar
highthroughput
sequenc
ribosom
rna
gene
enthusiast
adopt
research
commun
analys
polymicrobi
popul
includ
found
cf
airway
recent
perform
comparison
highthroughput
benchtop
sequenc
gs
junior
roch
miseq
illumina
ion
torrent
pgm
life
technolog
report
run
time
rang
h
n
h
gener
data
output
mbrun
although
research
studi
demonstr
consider
potenti
nextgener
sequenc
data
manag
process
current
present
signific
bottleneck
follow
run
complet
subsequ
bioinformat
analysi
output
data
requir
signific
time
expertis
would
routin
avail
clinic
laboratori
set
addit
discriminatori
power
rrna
gene
sequenc
alway
suffici
identif
bacteria
speci
level
yet
inform
may
requir
effect
clinic
treatment
exampl
identif
bcc
mycobacterium
spp
furthermor
migrat
sequenc
clinic
practic
would
involv
extra
degre
data
interrog
metagenom
sequenc
provid
comprehens
shotgun
view
individu
microbi
commun
interpret
biolog
data
determin
clinic
relev
highli
complex
requir
expert
judgement
therefor
order
fulli
realis
potenti
technolog
pathogen
identif
polymicrobi
infect
scheme
translat
largescal
data
output
clinic
use
report
need
develop
particular
mention
previous
clinic
relev
speci
would
determin
includ
quantit
threshold
indic
treatment
possibl
speci
interact
like
increas
pathogen
molecular
diagnosi
infect
use
mass
spectrometri
incorpor
multiplex
pcrrtpcr
step
target
amplif
follow
mass
spectrometri
analysi
amplicon
identifi
microb
target
present
sampl
current
exampl
abbott
plexid
tm
agil
masscod
pcr
system
recent
abbott
receiv
ce
mark
use
plexid
tm
three
diagnost
assay
intend
viral
bacteri
identif
plexid
viral
ic
spectrum
plexid
bac
spectrum
bc
plexid
flu
plexid
tm
system
work
determin
mass
pcr
amplicon
use
softwar
calcul
nucleotid
composit
sequenc
refer
known
molecular
mass
four
nucleotid
identif
comparison
databas
refer
sequenc
masscod
system
use
pcr
primer
label
uniqu
masstag
distinguish
molecular
weight
cleav
primer
uv
irradi
follow
target
amplif
unincorpor
primer
remov
masstag
retriev
amplicon
analysi
mass
spectrometri
identifi
target
amplifi
masscod
technolog
demonstr
potenti
detect
virus
bacteria
respiratori
sampl
present
restrict
research
applic
current
cf
diagnost
microbiolog
reli
culturedepend
method
detect
identif
microb
associ
cf
airway
infect
significantli
delay
result
deliveri
bias
diagnosi
toward
numer
easili
cultur
microb
may
necessarili
respons
poor
patient
health
approach
also
requir
highli
specialis
microbiolog
expertis
judgement
lead
inconsist
individu
laboratori
thu
cultureindepend
molecular
diagnost
direct
detect
multipl
infecti
agent
sputum
present
attract
prospect
improv
cf
patient
care
transit
tradit
culturedepend
method
molecular
method
would
requir
benefit
incur
outweigh
disadvantag
like
critic
molecular
assay
lack
cultur
prevent
immedi
characteris
identifi
pathogen
antibiot
suscept
test
strain
genotyp
identif
epidem
clone
p
aeruginosa
bcc
howev
could
argu
use
current
vitro
antibiot
suscept
test
predict
clinic
respons
question
potenti
molecular
method
predict
suscept
yet
thoroughli
explor
moreov
case
strain
type
cultur
isol
indic
rapid
molecular
test
would
allow
subsequ
followup
cultur
minim
time
loss
yet
molecular
test
suitabl
comprehens
cf
microbiolog
commerci
avail
although
potenti
suitabl
technolog
instrument
alreadi
exist
thu
assay
develop
valid
would
undertaken
process
involv
bring
molecular
assay
design
deploy
outlin
fig
regulatori
approv
ce
mark
fda
approv
essenti
market
vitro
diagnost
clinic
use
complex
assay
process
would
take
time
howev
success
multiplex
molecular
assay
infecti
diseas
diagnosi
demonstr
consider
potenti
futur
cf
assay
rapid
robust
test
automat
format
rang
throughput
level
judici
appli
diagnost
cf
sputum
microbiolog
costeffect
manner
molecular
technolog
may
futur
help
circumv
bottleneck
bia
associ
convent
cultur
improv
detect
clinic
relev
pathogen
